Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline <i>CHEK2</i> variantAlexandre Bazinet, François Mercier|Molecular Case Studies|2021Cited by 8
Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First RemissionAlexandre Bazinet, Tapan M. Kadia, Courtney D. DiNardo et al.|Blood|2024Cited by 4
A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)Luca Lanino, Vladan Vučinić, Anthony M. Hunter et al.|Blood|2024Cited by 3
<i>MECOM</i> fusion partner and bone marrow blast percentage influence outcomes of patients with <i>MECOM</i> rearranged acute myeloid leukaemiaWei‐Ying Jen, Tapan M. Kadia, Guilin Tang et al.|British Journal of Haematology|2025Cited by 3